Literature DB >> 8462563

In vitro susceptibility of quinolone-resistant Campylobacter jejuni to new macrolide antibiotics.

H P Endtz1, M Broeren, R P Mouton.   

Abstract

The MICs of erythromycin and three new macrolide antibiotics were determined for 36 quinolone-susceptible and 106 quinolone-resistant Campylobacter jejuni. The MIC90 values of azithromycin, clarithromycin, roxithromycin and erythromycin were 0.5, 4, 16 and 4 mg/l respectively. No difference was found between macrolide activity against the quinolone-susceptible and the quinolone-resistant strains. Clarithromycin and especially azithromycin might eventually replace erythromycin for the treatment of Campylobacter jejuni infections in view of their pharmacological properties.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8462563     DOI: 10.1007/bf01997058

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Short-term self-treatment of travellers' diarrhoea with norfloxacin: a placebo-controlled study.

Authors:  J Wiström; M Jertborn; S A Hedström; K Alestig; G Englund; B Jellheden; S R Norrby
Journal:  J Antimicrob Chemother       Date:  1989-06       Impact factor: 5.790

Review 2.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Characterization of high-level quinolone resistance in Campylobacter jejuni.

Authors:  T D Gootz; B A Martin
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

4.  Fluoroquinolone-resistance in thermophilic Campylobacter spp isolated from stools of Spanish patients.

Authors:  J Reina; P Alomar
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

5.  Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine.

Authors:  H P Endtz; G J Ruijs; B van Klingeren; W H Jansen; T van der Reyden; R P Mouton
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

6.  Susceptibility of Campylobacter fetus subsp. jejuni to twenty-nine antimicrobial agents.

Authors:  R Vanhoof; M P Vanderlinden; R Dierickx; S Lauwers; E Yourassowsky; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

7.  In-vitro activity of azithromycin against various Gram-negative bacilli and anaerobic bacteria.

Authors:  M D Kitzis; F W Goldstein; M Miégi; J F Acar
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

8.  Antimicrobial susceptibility of Campylobacter jejuni with special reference to resistance patterns of Canadian isolates.

Authors:  M A Karmali; S De Grandis; P C Fleming
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

9.  In vitro susceptibility of Campylobacter jejuni and Campylobacter coli isolated in Austria to erythromycin and ciprofloxacin.

Authors:  A M Hirschl; D Wolf; J Berger; M L Rotter
Journal:  Zentralbl Bakteriol       Date:  1990-04

10.  In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin.

Authors:  D E Taylor; N Chang
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

View more
  4 in total

1.  Development of resistance to macrolide antibiotics in an AIDS patient treated with clarithromycin for Campylobacter jejuni diarrhea.

Authors:  G Funke; R Baumann; J L Penner; M Altwegg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-07       Impact factor: 3.267

2.  Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides.

Authors:  R Sánchez; V Fernández-Baca; M D Díaz; P Muñoz; M Rodríguez-Créixems; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

3.  Azithromycin resistance in Campylobacter jejuni and Campylobacter coli.

Authors:  H Rautelin; O V Renkonen; T U Kosunen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-11       Impact factor: 3.267

Review 4.  Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.